 |
13 Companies | 25 Products |
|
|
25 Products | |
49 Diseases | |
150 Trials |  |
7500 News |  |
| 12345678910111213...166167» |
- | Journal: Urinary peptide analysis to predict the response to blood pressure medication. (Pubmed Central) - Apr 25, 2024
The DKDp189 model demonstrates potential as a predictive tool for guiding treatment with RASi in diabetic patients.
- | Journal: Association of Changes in Vector Length with Changes in Left Ventricular Mass Among Patients on Maintenance Hemodialysis: A Secondary Analysis of the Frequent Hemodialysis Network Daily Trial. (Pubmed Central) - Apr 24, 2024
The DKDp189 model demonstrates potential as a predictive tool for guiding treatment with RASi in diabetic patients. Change in vector length, a bioimpedance-derived proxy of volume status, was inversely associated with indices of left ventricular mass and volume measured by cardiac MRI in patients randomized to conventional or frequent hemodialysis over 12 months.
- | Journal: Production of Antioxidant, Angiotensin-Converting Enzyme Inhibitory and Osteogenic Gelatin Hydrolysate from Labeo rohita Swim Bladder. (Pubmed Central) - Apr 24, 2024
Both SBG and SBGH were rich in glycine, proline, glutamic acid, alanine, arginine, and hydroxyproline amino acids. Therefore, SBGH could be an effective nutraceutical in functional food development.
- || Review, Journal: Role and molecular mechanism of Salvia miltiorrhiza associated with chemical compounds in the treatment of diabetes mellitus and its complications: A review. (Pubmed Central) - Apr 23, 2024
The safety and tolerability of S miltiorrhiza have also been thoroughly investigated. Despite the established benefits of managing DM and its complications, further research is needed to determine appropriate usage, dosage, long-term health benefits, and safety.
- || omecamtiv mecarbil (AMG 423) / Amgen, Servier
Review, Journal: Challenging and target-based shifting strategies for heart failure treatment: An update from the last decades. (Pubmed Central) - Apr 23, 2024
Moreover, soluble guanylate cyclase stimulator, elamipretide, and omecamtiv mecarbil have come out as a next-generation therapeutic agent for patients with HF...Such tempting therapies still have some challenges to be addressed but may become a weighty option for treatment of HF. This review article will compile the paradigm shifts in HF treatment over the past dozen years or so and illustrate current landscape of antibody-based immunotherapy and gene therapy as a new therapeutic algorithm for patients with HF.
- | Retrospective data, Journal: Statins, ACE/ARBs drug use, and risk of pneumonia in hospitalized older patients: a retrospective cohort study. (Pubmed Central) - Apr 23, 2024
A higher effect was found among patients treated with ACE-I or ARBs in combination with statins (OR?=?0.67, 95% CI 0.52-0.85). This study confirmed in the real-world setting that these largely used medications may reduce the risk of pneumonia in older people, who chronically take them for cardiovascular conditions.
- | Journal: Supercritical carbon dioxide technology in food processing: Insightful comprehension of the mechanisms of microbial inactivation and impacts on quality and safety aspects. (Pubmed Central) - Apr 23, 2024
We highlight the opportunity for studies in postbiotic production. In conclusion, SC-CO2 technology may be used for microbial inactivation to ensure food safety without losing the quality parameters.
- || Review, Journal: Gastrointestinal: Small intestinal angioedema induced by angiotensin-converting enzyme inhibitors. (Pubmed Central) - Apr 22, 2024
In conclusion, SC-CO2 technology may be used for microbial inactivation to ensure food safety without losing the quality parameters. No abstract available
- enalapril / Generic mfg.
Enalapril malate (angiotensin-converting enzyme inhibitor) in drinking water reduces the expression of MHC I-K and II-A in the duodenal epithelia and delays the onset of type 1 diabetes in NOD mice. (Exhibit Hall F1; Poster Board Number: B593) - Apr 20, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_2747;
Morphometric analysis showed more islets without insulitis in EM-treat females (0.64mg/pancreas, n=16) than in CA-treat (0.53mg, n=17) and control females (0.36mg, n=18). mRNA of MHC-K and A genes in the duodenum and I-K and II-A expression on the pancreatic lymphocytes were reduced in the EM-treat mice.
- | Journal: Diabetes mellitus does not alter mortality or hospitalisation risk in patients with newly diagnosed heart failure with preserved ejection fraction: Time to rethink pathophysiological models of disease progression. (Pubmed Central) - Apr 20, 2024
mRNA of MHC-K and A genes in the duodenum and I-K and II-A expression on the pancreatic lymphocytes were reduced in the EM-treat mice. In unselected patients with newly diagnosed HF, diabetes is not an adverse prognostic marker in patients with HFpEF, but is in HFrEF.
- | Journal: Associations Between Hypertension, Angiotensin-Converting Enzyme Inhibitors, and Physical Performance in Very Old Adults: Results from the ilSIRENTE Study. (Pubmed Central) - Apr 19, 2024
The main findings of the present study indicate that ACEI use might influence the association between hypertension-related parameters and neuromuscular parameters in very old adults. Such results may possibly be linked to the effects of ACEI-p on the IGF-1 pathway.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal: Efficacy of early administration of sacubitril/valsartan after coronary artery revascularization in patients with acute myocardial infarction complicated by moderate-to-severe mitral regurgitation: a randomized controlled trial. (Pubmed Central) - Apr 18, 2024
Nevertheless, caution is needed to avoid hypotension. Chinese Clinical Trial Registry (ChiCTR2100054255) registered on December 11, 2021.
- | Journal: Olive Pomace Extract Contains Low Molecular Weight Peptides and Possesses ACE Inhibitory Activity. (Pubmed Central) - Apr 17, 2024
Olive pomace may represent a good source of peptides for nutritional and pharmaceutical applications. More research is needed in order to identify the in vivo effects of olive pomace bioactive peptides.
- | Journal: Different Kynurenine Pathway Dysregulation in Systemic Sclerosis in Men and Women. (Pubmed Central) - Apr 17, 2024
These results indicate differential KP activation in male and female SSc patients, with males demonstrating heightened KP activation. While ACE inhibitors may influence the KP in SSc patients, further research is necessary to comprehensively understand their impact on symptoms and prognosis in the context of these KP alterations.
- || Clinical, Retrospective data, Review: The Association between Use of Renin-Angiotensin-Aldosterone System Inhibitors and the Risk and Mortality of Pancreatic Cancer: A Systematic Review and Meta-Analysis. (Pubmed Central) - Apr 17, 2024
In summary, while renin-angiotensin-aldosterone system inhibitors did not appear to impact PC risk, their use was associated with lower PC mortality based on this meta-analysis of the current evidence. More rigorous and well-designed studies are required to validate and support these findings.
- || tranexamic acid oral / Generic mfg.
Clinical, Retrospective data, Journal: Tranexamic acid for angiotensin converting enzyme inhibitor induced angioedema: A retrospective multicenter study. (Pubmed Central) - Apr 16, 2024
Administration of tranexamic acid appears safe to use in ACE-I angioedema. Prospective randomized controlled studies should be considered to determine whether tranexamic acid is an effective treatment for ACE-I angioedema.
- | candesartan cilexetil / Generic mfg., enalapril / Generic mfg.
Journal: Impact of prior antihypertensive treatment on COVID-19 outcomes, by active ingredient. (Pubmed Central) - Apr 15, 2024
Prospective randomized controlled studies should be considered to determine whether tranexamic acid is an effective treatment for ACE-I angioedema. This large-scale real-world data study suggest that enalapril and candesartan are associated with a considerable reduction in risk of severe COVID19 outcomes.
- || Clinical, Journal: Electronic Health Record Population Health Management for Chronic Kidney Disease Care: A Cluster Randomized Clinical Trial. (Pubmed Central) - Apr 15, 2024
P=N/A
In this study, among patients with moderate-risk to high-risk CKD, a multifaceted electronic health record-based population health management intervention resulted in more exposure days to angiotensin-converting enzyme inhibitors/angiotensin receptor blockers but did not reduce risk of CKD progression or hypertension control vs usual care. ClinicalTrials.gov Identifier: NCT03832595.
- | trandolapril / Generic mfg.
Journal: ADAMTS13 deficiency exacerbates neuroinflammation by targeting matrix metalloproteinase-9 in ischemic brain injury. (Pubmed Central) - Apr 14, 2024
MMP-9 downregulation was achieved by using ACE inhibitors such as trandolapril...It showed that ADAMTS13 deficiency exacerbated ischemic brain injury through an MMP-9-dependent inflammatory mechanism. Therefore, the ADAMTS13-MMP-9 axis could have therapeutic potential for the treatment of AIS.
- | Journal: Evaluation of Alacepril Administration in Canine Patent Ductus Arteriosus According to Plasma Chymase Activity. (Pubmed Central) - Apr 13, 2024
Plasma chymase activity was affected and altered by alacepril. In veterinary medicine, plasma chymase activity may be a novel method for assessing the pathology of and therapy for cardiac diseases.
- | Journal: Optimization of Extraction Process and Activity of Angiotensin-Converting Enzyme (ACE) Inhibitory Peptide from Walnut Meal. (Pubmed Central) - Apr 13, 2024
After simulated gastrointestinal digestion in vitro, the ACE inhibitory rate of walnut peptide decreased significantly, but it still maintained over 90% ACE inhibitory activity. This study provides a reference for the application of low-molecular-weight walnut peptide as a potential antioxidant and ACE inhibitor.
- | captopril / Generic mfg.
Journal: Correlation Between the Severity of Coronary Artery Disease and Retinal Artery Disease and the Therapeutic Effect of Captopril. (Pubmed Central) - Apr 12, 2024
Concerning medication, the antihypertensive drug captopril demonstrated the potential to alleviate the severity of coronary artery and retinal artery lesions in hypertensive patients. However, specific treatment methods should be tailored to individual patient circumstances.
- | Journal: Evaluating prescription of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in patients with diabetes and albuminuria. (Pubmed Central) - Apr 12, 2024
ACEi/ARB therapy was suboptimal in patients with diabetes, hypertension, and albuminuria. Non-adherence was associated with CKD stage, possibly because of concerns about adverse events and healthcare-related factors.
- | Journal: N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction (Pubmed Central) - Apr 12, 2024
P=N/A
Post-discharge monitoring of NT-proBNP in HFpEF patients did not exhibit an association with reduced rates of HF hospitalization in this study. Nonetheless, it appears to enhance global clinical management by optimizing medical therapies and contributing to improved overall survival.
- | Journal, Monotherapy: Comparative safety and effectiveness of angiotensin converting enzyme inhibitors and thiazides and thiazide-like diuretics under strict monotherapy. (Pubmed Central) - Apr 12, 2024
While statistical significance is similarly lost for several safety outcomes, the safety profile of thiazides remains more favorable. Our results indicate a less striking difference in effectiveness of thiazides compared to ACEi and reflect some sensitivity to the monotherapy cohort definition modification.
- | temozolomide / Generic mfg.
Journal: Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma. (Pubmed Central) - Apr 11, 2024
Our results indicate a less striking difference in effectiveness of thiazides compared to ACEi and reflect some sensitivity to the monotherapy cohort definition modification. Both groups had worse survival with confusion/altered mental status (P
- || Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Retrospective data, Review, Journal: Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials. (Pubmed Central) - Apr 10, 2024
When compared to equivalent doses of ARB/ACEI, SV is not superior in reducing mortality and worsening heart failure. SV is superior when compared to sub-equivalent doses of ACEI.
- | Journal: Eligibility and Projected Benefits of Rapid Initiation of Quadruple Medical Therapy for Newly Diagnosed Heart (Pubmed Central) - Apr 10, 2024
SV is superior when compared to sub-equivalent doses of ACEI. In this nationwide U.S. cohort of patients hospitalized for newly diagnosed HFrEF, >4 of 5 patients were projected as eligible for quadruple therapy at discharge; yet,
- | perindopril arginine / Generic mfg., valsartan / Generic mfg.
Journal: Pharmacological inhibition of the ACE/Ang-2/AT1 axis alleviates mechanical ventilation-induced pulmonary fibrosis. (Pubmed Central) - Apr 10, 2024
Our finding indicated the ACE/Ang-2/AT1R axis played an essential role in the pathogenesis of MVPF. Pharmacological inhibition of the ACE/Ang-2/AT1R axis might be a promising strategy for the treatment of MVPF.
- | Journal: High pressure-assisted enzymatic hydrolysis potentiates the production of quinoa protein hydrolysates with antioxidant and ACE-inhibitory activities. (Pubmed Central) - Apr 10, 2024
The peptide sequences GSHWPFGGK, FSIAWPR, and PWLNFK presented the highest Peptide Ranker scores and were predicted to have ACE inhibitory, DPP-IV inhibitory, and antioxidant activities. Mild pressure levels were effective in producing QPH with enhanced functionality due to the effects of bioactive soluble phenolics and low molecular weight peptides.
- | Journal: The novel angiotensin-I-converting enzyme inhibitory peptides from Scomber japonicus muscle protein hydrolysates: QSAR-based screening, molecular docking, kinetic and stability studies. (Pubmed Central) - Apr 10, 2024
The zinc ions (Zn2+) and copper ions (Cu2+) enhanced ACE-I activity. The study suggests that the QSAR model is effective in rapidly screening for ACE-I inhibitors, and PLITT can be supplemented in foods to lower blood pressure.
- || Review, Journal: Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond. (Pubmed Central) - Apr 9, 2024
A multidimensional pharmacological approach targeting those pathophysiological mechanisms offers a complete and synergy approach to reducing SCD risk, thereby highlighting the importance of optimizing GDMT for HFrEF. The current landscape of HFrEF pharmacotherapy is evolving, with ongoing research needed to clarify the full extent of the anti-arrhythmic benefits offered by both existing and new treatments.
- | Journal: Quantification of endogenous Angiotensin 1-10, 1-9, 1-8, 1-7, and 1-5 in human plasma using micro-UHPLC-MS/MS: Outlining the importance of the pre-analytics for reliable results. (Pubmed Central) - Apr 8, 2024
In light of these discrepancies, we strongly advocate for rigorous pre-analytical considerations and comprehensive stability studies to ensure reliable results. We emphasise the pivotal role of heightened pre-analytical awareness within the clinical chemistry community, and we hope for continued growth in this critical area.
- | cardiotoxin (CB-6) / Celtic Biotech, MK-3795 / Merck (MSD)
Journal: Chronic hypoxia impairs skeletal muscle repair via HIF-2? stabilization. (Pubmed Central) - Apr 8, 2024
Administration of HIF-2? or ACE inhibitors may prove beneficial to ameliorate chronic hypoxia-associated muscle atrophy and weakness by improving muscle regeneration under chronic hypoxia.
- | Retrospective data, Journal: Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus. (Pubmed Central) - Apr 8, 2024
The present results contributed to a deeper understanding of the pathophysiology of ACEi-AE by (1) providing further evidence for the involvement of bradykinin signaling and coagulation pathways and (2) suggesting, for the first time, the involvement of the fibrinolysis pathway in this adverse drug reaction. An exploratory cross-ancestry comparison implicated the relevance of the associated risk loci across diverse ancestries.
- | Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories
Journal, HEOR: Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction. (Pubmed Central) - Apr 7, 2024
An exploratory cross-ancestry comparison implicated the relevance of the associated risk loci across diverse ancestries. No abstract available
- Implementation and Adherence to Cancer Therapy-Related Cardiovascular Toxicity Monitoring Protocol in Breast Cancer and Gynecologic Oncology Patients () - Apr 7, 2024 - Abstract #HOPA2024HOPA_150;
No abstract available In-Progress
- || Clinical, Review, Journal: Mineralocorticoid receptor antagonists in kidney transplantation. (Pubmed Central) - Apr 5, 2024
In-Progress Even though initial results regarding the role of mineralocorticoid receptor antagonist therapy for kidney transplant recipients are promising, there is clear need for large-scale randomized clinical trials with long-term follow-up data.
- || mycophenolate mofetil / Generic mfg.
Review, Journal: Immunoglobulin A glomerulonephropathy: A review. (Pubmed Central) - Apr 5, 2024
Patients with high and very high-risk profiles are treated with immunosuppressive therapy. A proteinuria level of < 1 g/d and stable/improved renal function indicates a good treatment response for patients on immunosuppressive therapy.
- || Review, Journal: SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway. (Pubmed Central) - Apr 5, 2024
The majority of the literature supports the current guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), European Society of Cardiology (ESC), and Heart Failure Society of America (HFSA), which state that ACEi and ARB medications should not be withdrawn from or initiated on patients with cardiovascular disease who are infected with SARS-CoV-2. More research needs to be conducted on the association between the emerging COVID-19 variants and ACEis/ARBs to give clinicians confidence when treating patients within this subgroup of the population.
- || Retrospective data, Review: Efficacy of traditional Chinese medicine versus angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and their combinations in the treatment of IgA nephropathy: a systematic review and network meta-analysis. (Pubmed Central) - Apr 5, 2024
Therefore, combination therapies can be used to enhance therapeutic outcomes based on individual patient circumstances, highlighting the use of TCM as a widely applicable approach in clinical practice. https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42023476674.
- carvedilol / Generic mfg.
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III () - Apr 5, 2024 - Abstract #SWOGSpring2024SWOG_Spring_57;
An interim futility analysis will be performed when 400 patients have been accrued to the randomized cohort. Summary Statement For the current status of this study, please refer to the Cancer Survivorship chapter.
- || ivabradine / Generic mfg.
Review, Journal: Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review. (Pubmed Central) - Apr 4, 2024
We also explored emerging drug therapies for HFpEF, such as sodium-glucose co-transporter 2 (SGLT2) inhibitors, angiotensin receptor-neprilysin inhibitor (ARNI), soluble guanylate cyclase (sGC) stimulators, novel MRAs, and ivabradine...Furthermore, long-term studies are essential to assess the durability and sustained benefits of emerging drug therapies. Identification of novel targets and mechanisms underlying HFpEF pathophysiology will pave the way for innovative drug development approaches in the management of HFpEF with concurrent hypertension.
- | Journal: Treatment Patterns, Outcomes, and Persistence to Newly Started Heart Failure Medications in Patients with Worsening Heart Failure: A Cohort Study from the United States and Germany. (Pubmed Central) - Apr 4, 2024
Identification of novel targets and mechanisms underlying HFpEF pathophysiology will pave the way for innovative drug development approaches in the management of HFpEF with concurrent hypertension. Morbidity, mortality, and rehospitalization risk is high among patients with worsening HF; uptake and continuation of GDMT is suboptimal.
- | Journal: National Trends in Hospital Performance (Pubmed Central) - Apr 4, 2024
Forty-two percent of patients did not receive all recommended HF medications at discharge, particularly women, minority patients, and those receiving care at urban hospitals. Rates of use increased over time, with variation in performance across hospitals.
- | Journal: Impact of Lactiplantibacillus plantarum and casein fortification on angiotensin converting enzyme inhibitory peptides in yogurt: identification and in silico analysis. (Pubmed Central) - Apr 3, 2024
plantarum M11 and sodium caseinate has the potential to be utilized as a functional food with antihypertensive properties. The combination of ACEIP-producing strains and casein fortification could be an effective method to promote the release of ACEIPs from yogurt.
- ACE Inhibitors and ARBs (W414) - Apr 3, 2024 - Abstract #ADA2024ADA_908;
- | Retrospective data, Journal: Prescribing cascades of antigout medications from thiazide diuretics in gout-na (Pubmed Central) - Apr 2, 2024
The combination of ACEIP-producing strains and casein fortification could be an effective method to promote the release of ACEIPs from yogurt. Gout-na
- || selonsertib (GS-4997) / Gilead, Olumiant (baricitinib) / Incyte, Eli Lilly
Review, Journal: Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression. (Pubmed Central) - Apr 1, 2024
We also explore the additional value of combing these therapies to develop novel treatment strategies. Drawing from the current understanding of DKD pathogenesis, we propose HIF inhibitors, AGE inhibitors, and epigenetic modifications as promising therapeutic targets for the future.
- | Journal: Associations between hypertension and cognitive, mood, and behavioral parameters in very old adults: results from the IlSIRENTE study. (Pubmed Central) - Mar 31, 2024
Furthermore, a lower concentration of inflammatory markers was found in hypertensive participants. ACEI use might affect this scenario.